With recent developments in anti-inflammasome therapies, some of which are even examined in clinical trials for diseases, such as AMD [17], our results add 3K3A-APC to the increasing list of NLRP3 inhibitors beneficial in ocular pathologies. This evidence concerns the gene NLRP3 and age-related macular degeneration.